Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
STOCKS
What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
By Adam Feuerstein
Dec 22, 2016 11:20 AM EST
PRESS RELEASES
Celldex Therapeutics To Present At 3rd Annual Evercore ISI HealthCONx Conference
By GlobeNewswire
Nov 30, 2020 4:01 PM EST
PRESS RELEASES
Celldex Therapeutics Initiates Phase 1b Study Of CDX-0159 In Chronic Spontaneous Urticaria
By GlobeNewswire
Oct 13, 2020 8:01 AM EDT
PRESS RELEASES
Celldex Therapeutics To Present At Upcoming Healthcare Conferences
By GlobeNewswire
Sep 10, 2020 4:01 PM EDT
PRESS RELEASES
Celldex To Report Second Quarter 2020 Financial Results And Host Corporate Update Call
By GlobeNewswire
Aug 3, 2020 8:01 AM EDT
PRESS RELEASES
Celldex Therapeutics Announces Closing Of $150.0 Million Public Offering Of Common Stock Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
By GlobeNewswire
Jun 18, 2020 10:31 AM EDT
PRESS RELEASES
Celldex Therapeutics Announces Pricing Of $130.4 Million Public Offering Of Common Stock
By GlobeNewswire
Jun 15, 2020 10:35 PM EDT
PRESS RELEASES
Celldex Therapeutics Announces Proposed Public Offering Of Common Stock
By GlobeNewswire
Jun 15, 2020 4:01 PM EDT
PRESS RELEASES
Celldex's KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions In Plasma Tryptase—an Indicator Of Mast Cell Burden—and A Favorable Safety Profile
By GlobeNewswire
Jun 6, 2020 3:01 AM EDT
PRESS RELEASES
Celldex Therapeutics Announces $1.7 Million Milestone Payment From Rockefeller University Related To Collaboration On HIV Antibody Program
By GlobeNewswire
Mar 3, 2020 8:01 AM EST
STOCKS
What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
By Adam Feuerstein
Dec 22, 2016 11:20 AM EST
STOCKS
2016 was a terrible year for biotech but the tweets were on point
By Adam Feuerstein
Dec 22, 2016 9:24 AM EST
STOCKS
Corbus Pharma bear thesis is alive and well
By Adam Feuerstein
Nov 15, 2016 6:55 AM EST
MARKETS
Celldex Therapeutics (CLDX) Stock Up on Q2 Results
By Kaya Yurieff
Aug 9, 2016 1:45 PM EDT
MARKETS
Celldex Therapeutics (CLDX) Is Strong On High Volume Today
By TheStreet Wire
Aug 9, 2016 10:00 AM EDT
MARKETS
Celldex Therapeutics (CLDX) In A Perilous Reversal
By TheStreet Wire
Jun 7, 2016 9:49 AM EDT
MARKETS
Celldex Therapeutics (CLDX) Marked As A Dead Cat Bounce Stock
By TheStreet Wire
Jun 6, 2016 9:45 AM EDT
STOCKS
Immunomedics Kicked Out of Prestigious ASCO Cancer Conference
By Adam Feuerstein
Jun 3, 2016 11:42 AM EDT
MARKETS
Celldex Therapeutics (CLDX): Today's Weak On High Volume Stock
By TheStreet Wire
Jun 3, 2016 10:02 AM EDT
MARKETS
Celldex Therapeutics (CLDX) Is Today's Strong On High Volume Stock
By TheStreet Wire
May 23, 2016 10:07 AM EDT
MARKETS
Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock
By TheStreet Wire
May 10, 2016 10:02 AM EDT
MARKETS
Celldex Therapeutics (CLDX) Weak On High Volume
By TheStreet Wire
May 5, 2016 10:03 AM EDT
STOCKS
Anavex Plays the Orphan Drug Stock Promotion Game
By Adam Feuerstein
Apr 12, 2016 7:00 AM EDT
MARKETS
Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock
By TheStreet Wire
Apr 7, 2016 10:03 AM EDT
MARKETS
Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's Strong On High Relative Volume Stock
By TheStreet Wire
Apr 4, 2016 10:00 AM EDT
